[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68, 394−24.
[2] Block KI, Gyllenhaal C, Lowe L, et al. Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol, 2015; 35, S276−304.
[3] The National Institute for Occupational Safety and Health (NIOSH). Hazardous drug exposures in healthcare. https://www.cdc.gov/niosh/topics/hazdrug/default.html. [2020-04-10].
[4] Quansah R, Jaakkola JJ. Occupational exposures and adverse pregnancy outcomes among nurses: a systematic review and meta-analysis. J Womens Health, 2010; 19, 1851−62.
[5] Direction de l’hospitalisation et de l’organisation des soins. Circulaire DHOS/SDO no 2005-101 du 22 février 2005 relative à l’organisation des soins en cancérologie. 2005-101.
[6] Le LMM, Reitter D, He S, et al. Safety analysis of occupational exposure of healthcare workers to residual contaminations of cytotoxic drugs using FMECA security approach. Sci Total Environ, 2017; 599-600, 1939−44.
[7] Chappuy M, Caudron E, Bellanger A, et al. Determination of platinum traces contamination by graphite furnace atomic absorption spectrometry after preconcentration by cloud point extraction. J Hazard Mater, 2010; 176, 207−12.
[8] Institut Pierre Louis UMR S 1136. BiostaTGV. https://biostatgv.sentiweb.fr. [2019-08-14].
[9] Kiffmeyer TK, Tuerk J, Hahn M, et al. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies - the MEWIP project. Ann Occup Hyg, 2013; 57, 444−55.
[10] Ndaw S, Hanser O, Kenepekian V, et al. Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination. Toxicol Lett, 2018; 298, 171−6.
[11] Crauste-Manciet S, Sessink PJM, Ferrari S, et al. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg, 2005; 49, 619−28.